Clinical trial
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All…
NCT00405054 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00405054 |
|---|---|
| Title | A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008) |
| Official title | A Phase II Study of MK0457 in Patients With T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | MK0457 |
| Enrollment | 52 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Nov 29, 2006 |
| Last update posted | Jan 26, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: